Inficon jumps 6% as J.P. Morgan starts at "overweight" on chip upcycle

J.P. Morgan initiated coverage of Inficon with an Overweight rating and CHF130 price target, implying ~29.7% upside to the March 31 close. The bank models 2025–2028 sales CAGR of ~10% and operating profit growth of 22%, setting 2027/2028 EPS at $5.85 and $6.71 (≈12% above Bloomberg consensus) and placing 2026 revenue at $720m (top end of company guidance $680–720m) with an 18.4% operating margin. Margins declined to 16.7% in 2025 from 20.3% in 2024 due to ~$10m tariff-related restructuring, FX headwinds (150–200bps) and dual-running costs (50–250bps), but JPM forecasts margin recovery to 21.4% in 2027 and 22.3% in 2028. Key risks highlighted include higher input/chip costs, rising Chinese competition (~25% China revenue), USD weakness vs CHF/EUR, stalled R&D and large-scale M&A.

Analysis

Inficon is a pure-play lever to the next semiconductor capital expenditure leg, but the real asymmetric payoff comes from its niche intellectual property in vacuum measurement and sensor calibration — not just WFE demand. That makes adjacent suppliers (precision sensors, vacuum pumps, thin-film consumables and metrology services) potential beneficiaries as fabs revalidate process stacks; expect procurement cycles to cascade through tier-2 vendors with a 3–9 month lag after OEM bookings.

Competitive pressure will be bifurcated: OEMs that can vertically integrate measurement functions will compress margins for independent subsystem vendors, while incumbents with entrenched IP and long qualification cycles will enjoy stickier pricing — the difference will show up in gross-margin trajectories over the next 12–24 months. Currency moves and lingering dual-production costs create a timing mismatch between order intake and reported margins, so near-term P&L volatility can mask multi-year operating leverage.

Near-term catalysts to watch are booking momentum from Asian foundries, confirmation of content wins at new nodes, and any public evidence of Chinese local substitutes passing qualification. Tail risks that could abruptly reverse the thesis include accelerated Chinese domestic tool adoption, unexpected input-cost inflation (modules or custom ASICs), and adverse FX moves; these are binary over 6–18 months.

From a positioning standpoint, the market seems to underweight the optionality from structural margin recovery once restructuring and dual-run costs roll off, but it also underestimates the pace at which lower-cost Chinese alternatives can capture share if R&D cadence slips. Use operational readouts (order backlog, margin guidance, R&D hiring) as real-time signals to reprice the trade rather than headline brokerage notes.

Key Decisions for Investors

• Long IFCN (SIX:IFCN) equity, 12–18 month horizon: allocate a modest position (2–3% NAV) to capture multi-year margin reset and WFE upside; set tactical stop-loss at 18% and trim into signs of order-book deceleration. Reward scenario: high-single to low-double digit annualized upside if node-cycle accelerates and restructuring costs fade.
• Call spread on IFCN, 6–9 months: buy a near-term call and sell a higher-strike call to finance premium — offers 2–3x asymmetric payoff into a positive bookings print while capping downside to option premium. Use this ahead of quarterly results or major trade shows where order disclosures occur.
• Pair trade: long Swiss/European niche sub-system suppliers (e.g., IFCN) / short select China-exposed low-innovation subs (size matched), 9–12 months: this isolates WFE cyclicality from structural margin risk caused by domestic competition. Monitor R&D hiring and qualification wins; unwind if Chinese vendors post unexpected qualification successes.
• Hedge FX exposure: overlay a 6–12 month USD/CHF hedge (forward or options) sized to expected FX translation risk to protect reported EUR/CHF revenue converted into USD — cost is justified if CHF weakens and compresses USD-reported upside.
• Event trigger rule: if quarterly order intake declines >15% QoQ or R&D spend is cut materially, reduce gross exposure by 50% within one week to protect against rapid market-share erosion; conversely, if order backlog growth accelerates >20% and gross margins expand sequentially, add up to another 1–2% NAV within 30 days.